Company
Grifols
Grifols has 35 drugs tracked on RxWires: 6 post-market, 16 in Phase 3, 1 in Phase 2/3, 9 in Phase 2, 1 in Phase 1/2, 1 in Phase 1.
Pipeline
| Drug | Phase | Indication |
|---|---|---|
| IGSC 20% | Post-Market | Primary Immunodeficiency |
| Albumin | Post-Market | Cirrhosis |
| IVIG | Post-Market | Myasthenia Gravid |
| plasma-derived FVIII/VWF concentrate | Post-Market | Von Willebrand Disease |
| Alphanate SD/HT | Post-Market | Severe Hemophilia A |
| Tetanus Immune Globulin (Human) | Post-Market | Tetanus |
| Xembify | Phase 3 | Hypogammaglobulinemia |
| Alpha-1 MP | Phase 3 | Alpha 1-Antitrypsin Deficiency |
| IGIV3I Grifols 10% | Phase 3 | Idiopathic Thrombocytopenic Purpura |
| FIB Grifols | Phase 3 | Congenital Afibrinogenemia |
| Intravenous Immunoglobulin | Phase 3 | Autoimmune Epilepsy |
| Gamunex-C | Phase 3 | CIDP (Chronic Inflammatory Demyelinating Polyradiculoneuropathy) |
| Fibrin Sealant Grifols | Phase 3 | Parenchymous Tissue Surgical Bleeding |
| IGIV-C 10% | Phase 3 | Primary Immunodeficiency |
| Albutein 20% | Phase 3 | Decompensated Cirrhosis and Ascites |
| Methotrexate | Phase 3 | Pediatric Crohn's Disease |
| Alpha-1 15% | Phase 3 | Alpha 1 Antitrypsin Deficiency |
| Hepatitis B immune globulin | Phase 3 | Hepatitis B |
| IGIV-C | Phase 3 | Myasthenia Gravis Exacerbations |
| IGIV3I Grifols | Phase 3 | Immune (Idiopathic) Thrombocytopenic Purpura |
| Immune Globulin IV (Human), 10% Caprylate/Chromatography Purified | Phase 3 | Polyradiculoneuropathy, Chronic Inflammatory Demyelinating |
| Ciprofloxacin dispersion for inhalation | Phase 3 | Non Cystic Fibrosis Bronchiectasis |
| Albumin 5% | Phase 2/3 | Alzheimer's Disease |
| Convalescent anti-SARS-CoV-2 MBT Plasma | Phase 2 | COVID-19 |
| Antithrombin III | Phase 2 | Antithrombin III Deficiency |
| Immune Globulin Intravenous [Human], 10% Caprylate/Chromatography Purified | Phase 2 | Macular Degeneration |
| Prolastin | Phase 2 | COVID-19 |
| Albumin infusion (25% albumin) | Phase 2 | Cirrhosis |
| Human thrombin | Phase 2 | Hemostasis |
| Plasmin | Phase 2 | Acute Peripheral Arterial Occlusion |
| Liquid Alpha1-Proteinase Inhibitor (Human) | Phase 2 | COVID-19 |
| GRF312 5% | Phase 2 | Dry Eye Disease |
| Human Plasma-Derived Fibrinogen Concentrate | Phase 1/2 | Congenital Afibrinogenemia |
| RIG-C | Phase 1 | Rabies |
| Gamimune N or Gamunex 10% | Not Applicable | Miscarriage, Recurrent |
Latest
No recent events.
Follow Grifols on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.